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Background: Syphilis infection during pregnancy leads to avoidable morbidity and mortality and remains a
significant problem in sub-Saharan Africa. Despite global initiatives to increase the proportion of pregnant women
screened, implementation has been slow. We sought to investigate the feasibility of adding syphilis screening
within an integrated antenatal HIV clinic.
Methods: Pregnant women attending the HIV antenatal clinic were sequentially enrolled and consenting participants
answered a questionnaire on sexual behavior and previous pregnancies, provided sociodemographic data, and were
tested using rapid plasmin reagin (RPR). If positive, participants were treated with benzathine penicillin. All were given a
partner notification slip and were followed up after delivery to determine birth outcomes.
Results: 584 of 606 (95.7%) women approached and consented to test for syphilis. 570 women were enrolled (median
age 29 (IQR 25–32) with a median (IQR) CD4 of 372 (257–569) cells/μL). Of the 5.1% (29/570) with a positive RPR,
all were asymptomatic, were successfully contacted, and treated with benzathine penicillin without adverse reactions.
Overall, 61 (12.1%) of the participants had an adverse birth outcome. In the bivariate analysis, only age was significantly
different between those with and without a positive RPR (RR = 1.15, 95% CI 1.065-1.248; p < 0.001). Partners of only 10
(34.5%) participants returned for treatment.
Conclusions: Structural interventions such as opt-out testing for syphilis within integrated HIV-antenatal care clinics are
feasible and capitalize on the excellent care programs that have already been established for HIV care. Novel approaches
are required for partner notification.
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Pregnant women who are infected with Treponema palli-
dum, the causative bacterial organism of syphilis, are at
high risk for adverse birth outcomes. It is estimated that
without screening and treatment, 53-82% of these women
will have negative outcomes including late abortion, still-
birth, prematurity, low birth weight, neonatal death, and
congenital syphilis [1]. In sub-Saharan Africa (SSA), there
are approximately 535,000 pregnant women with active
syphilis yearly [2]. A meta-analysis by Hawkes and col-
leagues estimated that the antenatal syphilis screening* Correspondence: ymanabe@jhmi.edu
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unless otherwise stated.interventions could reduce the incidence of syphilis-
related perinatal death and stillbirth by ~50% globally with
the majority of the benefit in low and middle-income
countries [3,4]. However, despite the launch of the World
Health Organization (WHO) global initiative to eliminate
congenital syphilis [5] and widespread policies for syphilis
screening in most developing countries, implementation
of syphilis screening has been slow due to inadequate and
centralized laboratory services [6]. Global estimates from
the WHO showed wide variation among African countries
with 34% to >95% of women accessing antenatal care of
which 3% to >95% of pregnant women were screened for
syphilis [7].
HIV clinics offer opportunities to screen for other preva-
lent infectious diseases. As a regular point of contact be-
tween health care workers and patients, integration in thesel. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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resources. As sub-Saharan African countries implement
prevention-of-mother-to-child transmission (PMTCT) pro-
grams such as option B (antiretroviral therapy (ART) to
pregnant women at any CD4 count for pregnancy and
breast feeding) and option B plus (ART to pregnant women
for life at any CD4 count) in accordance with the 2013
WHO guidance [8], HIV clinics are becoming more fre-
quently involved in providing integrated antenatal and HIV
care. This integration of sexual and reproductive health
(SRH) services in HIV care provides an opportunity to offer
other services such as family planning, sexually transmitted
infection and cervical cancer screening within the HIV
clinic setting. However, there is very little operational re-
search data on outcomes and processes of integrating SRH
services into mainstream HIV care. The WHO recently
endorsed integrated syphilis and HIV screening in antenatal
clinics for the elimination of mother-to-child transmission
of both syphilis and HIV [9].
In Uganda, it is estimated that 1.8% of pregnant women
are infected with syphilis based on a country wide serosur-
vey, however less than 2% of pregnant women are tested
in pregnancy [6,10]. Following success in establishing an
integrated tuberculosis-HIV clinic which reduced tubercu-
losis treatment default [11], we sought to integrate SRH
care into our HIV services. An early focus was to extend
syphilis testing to all pregnant women attending an in-
tegrated antennal HIV clinic. This paper describes the
feasibility of an integrated approach to syphilis screening
within an antenatal HIV clinic and highlights the major
barriers to wider roll-out and implementation.
Methods
Study setting and design
We performed a descriptive cohort study of consecutive,
HIV-infected pregnant women who were followed at the
Infectious Diseases Institute (IDI) in Kampala, Uganda. IDI
is a clinical and research center of excellence that sees more
than 350 patients per day, has approximately 9,000 patients
enrolled in HIV care and more than 7,000 on ART. Patients
were prospectively recruited and investigated upon referral
to the antenatal clinic which is integrated within the adult
IDI HIV clinic. Four weeks prior to delivery, women trans-
ferred care to the Mulago National Referral Hospital ante-
natal outpatient clinic. All participants provided written
informed consent and the study was approved by the
Makerere University Research and Ethics Committee as
well as the Uganda National Council of Science and Tech-
nology. Patients were eligible for the study if they were con-
firmed to be pregnant, and were registered at the IDI clinic.
Procedures
Demographic characteristics were recorded and a standar-
dized questionnaire was completed, documenting sexuallytransmitted infection symptoms, sexual behavior, previous
birth outcomes, relevant obstetric and prenatal histories,
and most recent CD4 T cell count. Each patient provided
a venous blood sample for non-treponemal assay testing
(rapid plasma reagin, RPR, Taytec, Canada) in the clinic
stat laboratory. RPR was the Ugandan standard at time of
the study. All women who were confirmed to be RPR-
positive were contacted to return to clinic and were
treated with one intramuscular injection of 2.4 million
units benzathine penicillin per the Ugandan national treat-
ment guidelines for syphilis. Mothers who were penicillin-
sensitive were treated with erythromycin 500 mg four
times per day for ten days. All patients with a positive RPR
were given an anonymized partner notification slip and
encouraged by the nurse counselors to invite their part-
ners to return to the IDI clinic for free treatment. Risk of
reinfection was emphasized. The slip explained to the
partner that they may have been exposed to a sexually
transmitted infection and that they should seek medical
follow-up.
Women with syphilis were followed up according to
the Ministry of Health recommended routine antenatal
schedule, although many patients were seen more fre-
quently if they were on ART for HIV, for example. Parti-
cipants were either contacted by phone within 30 days
of the estimated due date to follow up on pregnancy
outcome or reviewed by a clinician at the IDI clinic if
they had a return appointment scheduled. Participants
were not monetarily compensated for their time.
Treponemal antibody testing (Determine Syphilis TP,
Alere, Japan) was then retrospectively performed as
batched testing in the Makerere University-Johns Hopkins
University clinical core laboratory which is College of
American Pathologists (CAP) certified and undergoes ex-
ternal proficiency testing as well as on-going daily internal
quality assurance procedures.
The data was double data entered by data entrants and
analyzed by STATA (Stata Corp. STATA 11.1, College
Station, Texas, USA). Descriptive statistics were used for
the demographic and obstetric characteristics. Patients
with a positive RPR test were compared to those who
tested negative using chi-squared test and Wilcoxon rank
sum test.
Results
Patient characteristics
Patients were recruited from October, 2010 through
December 2011 (Figure 1). Six hundred and six consecu-
tive, pregnant, HIV-infected women were approached to
enroll in the study within the IDI antenatal clinic. Five
hundred eighty-four (95.7%) women consented to partici-
pate and underwent syphilis testing; 14 were tested on 2
occasions. Among the 570 unique participants, the median
age was 29 years (IQR 25–32), 93.5% (533) had either a
Figure 1 Study enrollment diagram.
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women were ever married with 30.7% (175) currently liv-
ing with their spouse. The majority of the women were
employed (59.1% (337)). Most of the participants presented
for syphilis testing in the first or second trimesters (418/
570, 73.3%) and 15.0% (86) were primagravida (Table 1).
Twenty-two participants presented to the HIV clinic for
the first time at the time of pregnancy.
The median CD4 of the participants overall was 402
(IQR 272–575) cells/μL. For the more than half (54.2%) of
participants on ART, the median (IQR) CD4 was 372
(257–569) cells/μL and 426 (299–598) cells/μL for partici-
pants not on ART. Of the women taking ART, 81.4%
(275) were on a non-nucleoside reverse transcriptase in-
hibitor (NNRTI)-based regimen, 17.1% (58) on a protease
inhibitor (PI)-based regimen, and 1.5% (5) on nucleoside
reverse transcriptase inhibitor (NRTI)-based regimen only.
Prevalence and factors associated with a positive RPR in
pregnant HIV-infected women
A positive RPR was found in 5.1% (29/570) of the partici-
pants, none of whom were symptomatic for primary or
secondary syphilis. All 29 were successfully contacted and
treated with benzathine penicillin and did not have ad-
verse reactions. Twenty-eight of the 29 participants with a
positive RPR were able to be contacted post-partum.
Three (10.7%) of the RPR-positive participants had spon-
taneous abortions, and no stillbirths, premature births, or
early deaths. In the RPR-negative group, 505 (of 541, 93%)
participants were able to be contacted post-partum. Of
these, 17 (3.4%) had a premature birth, 23 (4.6%) had a
spontaneous abortion, 11 (2.2%) had a still birth, and 10
(2.0%) participants had the baby die within 7 days of birth.
Overall, 61 (12.1%) had an adverse birth outcome. In the
bivariate analysis, only age was significantly different be-
tween those with and without a positive RPR (RR = 1.15,95% CI 1.065-1.248; p < 0.001); RPR positive participants
tended to be younger.
For the 84.9% (484/570) of the participants who had pre-
viously been pregnant, 5.0% (24/484) were RPR-positive
this pregnancy. There were no adverse birth events for
those with a positive RPR test. Only 2.8% of the patients
with a negative RPR reported a previous adverse outcome.
62 (12.8%) had been treated previously for sexually trans-
mitted infections. Confirmatory testing with a treponemal
antibody was done retrospectively and found only 34%
(10/29) were positive by the confirmatory test with an
overall rate of confirmed syphilis of only 1.8% (10/570).Uptake of syphilis screening in partners of RPR-positive
patients
Of the 29 participants with a positive RPR test, only 17
(58%) agreed at time of treatment to notify their partners.
Of these, only 10 (58.8%) partners returned for counseling,
testing and treatment.Discussion
Overall rates of syphilis in our study were comparable to
the Uganda Bureau of Statistics AIDS indicator survey of
2011 [12] and antenatal syphilis prevalence rates re-
ported in other Ugandan studies [10,13]. By integrating
the syphilis screening into routine antenatal care in our
HIV clinic, we achieved widespread screening of syphilis
in pregnancy with no requirement for additional human
resources. All women who were found to be positive
were notified and received treatment, thereby potentially
avoiding syphilis-associated maternal and infant morbid-
ity and mortality. However, the number of women with
a positive test was not large enough to show an impact
on birth outcomes. Among the women with syphilis
who had previously been pregnant, none had received
Table 1 Demographic characteristics of the participants
Variable Syphilis stage blood test P-value
RPR-negative (n = 541) RPR-positive (n = 29) Total (n = 570)
Age of respondents: median(IQR) 29(25–32) 25(22–27) 29(25–32) <0.001
CD4 count at diagnosis: median(IQR) 400(274–577) 433(255–553) 402 (272–575) 0.867
On ART at time of syphilis testing 324 (59.9) 14 (48.3) 338 0.211
NNRTI-based 264(81.4) 11(78.6) 275(81.3)
PI-based 55(17.0) 3(21.4) 58(17.1)
NRTI-based 5(1.5) 0 5(1.5)
Duration since start of ART (weeks) 101.1(5.1-209.6) 28.9(2-89 93.8(4.8-208.4) 0.265
BMI 23.1(4.2) 21.3(2.9) 23.0(4.2) 0.118
Number of previous pregnancies 460 24 484 0.341
1 152(33.0) 10(41.7) 162(33.5)
2-3 216(47.0) 12(50) 228(47.1)
≥4 92(20.0) 2(8.3) 94(19.4)
Level of education 0.423
none 34(6.3) 3(10.3) 37(6.5)
primary 222(41.0) 14(48.3) 236(41.4)
secondary 285(52.7) 12(41.4) 297(52.1)
Marital status 0.437
single 20(3.7) 0 20(3.5)
ever married* 357(66.0) 18(62.1) 375(65.8)
co-habiting 164(30.3) 11(37.9) 175(30.7)
Employed 321(59.3) 16(55.2) 337(59.1) 0.657
Had sex in the last 1-month 408(75.4) 22(75.9) 430(75.4) 0.957
Partner agrees to use a condom 326(79.9) 16(72.7) 342(79.5) 0.417
Used a condom during the last sexual encounter 254(62.2) 13(59.1) 267(62.1) 0.773
Previously treated for STI's 67(12.4) 4(13.8) 71(12.5) 0.823
Received PMTCT 297(54.9) 12(41.4) 309(54.2) 0.182
Hospitalized during this pregnancy 6(1.1) 1(3.4) 7(1.2) 0.308
Hypertension during this pregnancy 2(0.4) 1(3.4) 3(0.5) 0.145
*includes married, separated/divorced, and widowed.
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births had an adverse outcome by participant recall.
As well as increased syphilis testing, our experience of
integrating sexual and reproductive health into HIV care
also increased the proportion of women who were offered
PMTCT option B amongst those not already on ART
(data not shown). Likewise in Zambia, combined research
and service delivery programs had a positive influence on
RPR testing (OR 2.5 (95% CI 2.1-3.0)) [14], and in
Mozambique, a longitudinal study showed that integrated
efforts of syphilis screening into antenatal care was super-
ior to a vertical program in increasing nationwide rates of
syphilis screening among pregnant women [15].
In our resource-limited setting, a possible barrier to test-
ing is the availability of validated methods of syphilis test-
ing that are easy to perform and easy to interpret. Therehas been a long standing debate about non-treponemal
test (RPR) as the screening test of choice for antenatal
syphilis; RPR is time-intensive, requires lab expertise to
perform, and electricity for a rotator. There is also a high
false positive rate and, ideally, RPR positive patients should
have a confirmatory treponemal test. However, more spe-
cific treponemal tests remain positive for life, which can
overestimate active syphilis and may lead to overtreatment
of pregnant women where resources are scarce. Con-
versely, treponemal tests cannot differentiate between an
old treated infection and reinfection, which is also a chal-
lenge in sexually active pregnant women. The RPR false
positivity rate was unusually high in our study suggesting
biologic false positives due to pregnancy [16], HIV [17], or
other mechanisms including uncontrolled temperature
and humidity in the stat lab where the RPRs were
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titers are prohibitively expensive and, therefore, were not
performed. In our cohort, we used traditional lab-based
RPR testing, but did still manage to have a good uptake of
syphilis testing and treatment implemented by HIV
clinicians.
In our study, 75% of women had sex in the last month
and only 38% of these did not use a condom. However,
despite intensive counseling, we found that it was diffi-
cult to get participants with syphilis to notify their part-
ners (58%). Ultimately only one-third of the partners
came in for testing and treatment. Our intensive coun-
seling did result in higher uptake than has previously
been reported in the literature. In an implementation
study in Uganda, <1% of partners of pregnant women
who were offered testing ultimately came to clinic for
HIV and syphilis testing [18]. In another evaluation in
Zambia and Uganda in both rural and urban sites, 9.9%
of men who were invited to test did so [10]. This has im-
portant implications for the roll-out of rapid syphilis
testing and treatment, as reinfection (especially before
delivery) is a serious concern in pregnant women. Use of
treponemal tests in this situation is also debatable due to
the inability to detect reinfection. In another assessment
of routine syphilis screening in Mozambique, low rates
of partner notification were also reported [15]. Inte-
grated care led to significant screening in first and sec-
ond trimester, although we acknowledge that we should
also have introduced a retesting strategy for later trime-
sters. Intensive counseling combined with repeated noti-
fications of the pregnant woman may increase partner
testing rates. We are currently undertaking a study to
assess novel strategies to address this issue (clinical
trials.gov NCT02262390).
Authors from a recent review have suggested that the
rapid elaboration of new point-of-care (POC) tests to en-
compass screening for multiple STIs may be both war-
ranted and feasible [13]. The introduction of rapid, POC
treponemal antibody testing will allow for screening in more
peripheral facilities because the immunochromatographic
tests strips detect serum antibodies to recombinant T. palli-
dum specific antigens and are reliable, rapid (8 minutes)
and do not require refrigeration or specialized equipment
[19-22]. Data from South Africa show that rapid testing
may also increase the proportion of patients who test and
are treated for syphilis [23]. The structured introduction of
POC syphilis testing will make antenatal syphilis screening
even more accessible as it will circumvent challenges in
laboratory infrastructure needed for RPR testing in
resource-limited settings [6,10,24]. It will make implementa-
tion of STI screening easier for health care workers in
resource limited settings, and will enable same day results,
which can assist in uptake of treatment. There are currently
5 manufacturers that have integrated HIV and syphilistesting in the same POCT test (23) and once validated and
widely available, these will be an additional step in the inte-
gration of SRH activities. Challenges remain in the propor-
tion of women who access antenatal care throughout sub-
Saharan Africa [25], but with new PMTCT initiatives this
should improve. We need to seize the opportunity of this
roll out, and the training of health care workers during this
period to integrate syphilis screening with HIV testing [26]
into PMTCT B and B plus programs.
Conclusion
Structural interventions such as opt-out testing for syphilis
integrated within HIV services capitalize on the excellent
vertical care programs that have already been established
for HIV care and are feasible.
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